Dopamine, dopaminergic drugs and ocular hypertension

Abstract

The study refers to the clinical experiences performed with several D1 and D2 dopaminergic receptors agonists in 20 patients with high tension open angle glaucoma. The substances were administered topically as eye drops as well as an ocular eye bath. The parameter examined was intraocular pressure (IOP). The substances taken in consideration were: Dopamine, Ibopamine (dopamine analog), Fenoldopam and 3B90 (D1-receptor agonists) and Bromocriptine (dopaminergic agonist with higher affinity for D2 than for D1-receptors). It has been shown that all selective D1-receptors agonists induce a significant increase in IOP only in eyes with hydrodynamic disorders (p < 0.001). Such hypertensive effects could not be antagonized either by topically administered dopaminergic antagonists (Sulpiride, D2-receptors antagonist, and Haloperidol, non-selective dopaminergic antagonist) or by the pretreatment with the commonly used topical antiglaucomatous drugs. The only substance which proved able to inhibit the IOP increase induced by the D1-receptors agonists was the D1-selective antagonist SCH-23390, suggesting that IOP increase may be a result of a stimulation of the D1-receptors. The authors hypothesize that dopaminergic system may play a role in the regulation of aqueous humor hydrodynamics.

Ibopamine Eye Drops In Ophthalmology

“…Of note, this increase in IOP is not dependent upon the mydriatic effect of the drug, since it cannot be inhibited by the administration of α-blockers [4]. Conversely, the increase in IOP can be attributed to D1-dopaminergic activity [31]. In more details, the increase in aqueous humor induced by the action of ibopamine on dopaminergic receptors is compensated by a corresponding outflow in the healthy eye, but not in the glaucoma eye [32].…”

“…Conversely, the increase in IOP can be attributed to D1-dopaminergic activity [31]. In more details, the increase in aqueous humor induced by the action of ibopamine on dopaminergic receptors is compensated by a corresponding outflow in the healthy eye, but not in the glaucoma eye [32].…”

“…This dose-dependent effect reaches its peak within 45 minutes from the first instillation and lasts about 180 minutes, without any painful symptom or ocular discomfort [18]. Of note, this increase in IOP is not dependent upon the mydriatic effect of the drug, since it cannot be inhibited by the administration of α-blockers [4]. Conversely, the increase in IOP can be attributed to D1-dopaminergic activity [31].…”

“…In line of principle, the use of ibopamine in this setting can be extended also to the pediatric population, thanks to its excellent safety profile [16].…”

Teste da ibopamina tópica em pacientes normais, suspeitos e portadores de glaucoma

“…O efeito hipertensivo da ibopamina tópica é transitório (150 a 180 minutos) e não está relacionado à midríase e sim, ao aumento da produção de humor aquoso (3)(4)(5)(6) .…”